12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Company News  |  Deals

FoldRx, Pfizer deal

Pfizer will acquire FoldRx for an undisclosed upfront payment plus potential milestones. Pfizer gains FoldRx's lead candidate, tafamidis, a small molecule that stabilizes transthyretin (TTR) protein and prevents misfolding. The compound...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >